Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Goodman on the Role of PD-1 Inhibitors in T-Cell Lymphomas

March 19th 2020

Aaron Goodman, MD, discusses the role of PD-1 inhibitors in T-cell lymphomas.

Expert Highlights Multitargeted Treatments in Hematologic Malignancies

March 18th 2020

David S. Hong, MD, discusses the burgeoning role of multitargeted therapeutics in patients with hematologic malignancies.

FDA Grants ALPN-101 Orphan Drug Designations in GVHD

March 18th 2020

The FDA has granted 2 Orphan Drug Designations to ALPN-101 for the prevention and treatment of acute graft-versus-host-disease.

Dr. Miklos on the Results of the ZUMA-2 Trial in MCL

March 18th 2020

David Miklos, MD, discusses the results of the phase II ZUMA-2 trial with KTE-X19 in mantle cell lymphoma.

Dr. Abdul Hay on the Evolving Role of Transplant in ALL

March 18th 2020

Mohammad Maher Abdul Hay, MD, discusses the evolving role of transplant in acute lymphoblastic leukemia.

Dr. Cutler on Treatment Options for Acute and Chronic GVHD

March 18th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses treatment options for patients with acute and chronic graft-versus-host disease.

Dr. Westin on the Role of R-CHOP in DLBCL

March 18th 2020

Jason Westin, MD, MS, FACP, discusses the role of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Taking a Practical Approach to Acute GVHD

March 17th 2020

Although acute graft-versus-host disease remains potentially fatal for patients who undergo allogeneic hematopoietic stem cell transplantation, prevention and treatment strategies for this complication are evolving.

AXL Kinase Becomes a Therapeutic Target in Its Own Right

March 17th 2020

Despite being implicated across the spectrum of cancer hallmarks, aberrant AXL signaling is just starting to emerge as a distinct anticancer target, with a growing focus on specific inhibitors as well as alternative novel drug designs.

Dr. Abdul-Hay on Treatment Considerations in ALL

March 17th 2020

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health’s Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center, discusses treatment considerations in acute lymphoblastic leukemia (ALL).

Dr. Hamdan on Trial of Brentuximab Vedotin/Chemo in HIV-Associated Hodgkin Lymphoma

March 17th 2020

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses a pilot phase I/II trial with brentuximab vedotin (Adcetris) plus chemotherapy in patients with HIV-associated Hodgkin lymphoma.

Dr. Grossbard on the GALLIUM Study in Follicular Lymphoma

March 17th 2020

Michael L. Grossbard, MD, professor in the Department of Medicine, chief of the Hematology and Medical Oncology Inpatient Service at Tisch Hospital, and section chief of Hematology at NYU Langone Health’s Perlmutter Cancer Center, discusses the results of the phase III GALLIUM study in follicular lymphoma.

A Myeloma Pioneer Sees More Innovation

March 16th 2020

Kenneth C. Anderson, MD, discusses key trials in multiple myeloma that have reported promising findings or are poised to shed light on novel treatments.

Dr. Desai on Evolving Treatment Approaches in Lymphomas

March 13th 2020

Sameer Desai, MD, discusses current and emerging treatment options under evaluation in lymphomas.

Dr. Westin on Potential for Chemo-Free Treatment in Large Cell Lymphoma

March 13th 2020

Jason Westin, MD, MS, FACP, discusses the potential for a chemotherapy-free future in large cell lymphoma.

Dr. Abdul-Hay on the Use of BiTEs in ALL

March 11th 2020

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health’s Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center, discusses the use of bispecific T-cell engagers (BiTEs) in acute lymphoblastic leukemia (ALL).

Dr. Patel on the Unmet Need of FLT3 Inhibitors in AML Treatment

March 10th 2020

Prapti Patel, MD, discusses the unmet need of FLT3 inhibitors in the treatment of patients with acute myeloid leukemia.

BiTEs and CAR T Cells Burst Through ALL Paradigm

March 9th 2020

Mohammad Maher Abdul-Hay, MD, discusses current standards for the treatment of patients with acute lymphocytic leukemia.

GVHD Armamentarium Expanding, But Novel Treatments Still Needed

March 6th 2020

Madan Jagasia, MBBS, MS, MMHC, discusses the current treatment landscape and next steps in graft-versus-host-disease.

FDA Grants Umbralisib Orphan Drug Status in Follicular Lymphoma

March 6th 2020

The FDA has granted an orphan drug designation to umbralisib for the treatment of patients with follicular lymphoma.